{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-287698","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2022-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.975388+00:00","generated_at":"2026-06-21T16:44:48.921959+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inhibikase Q3 net loss $4.49M; FDA clinical hold on IkT-148009 programs","bullets":["Q3 2022 net loss of $4.49M ($0.18 per share) vs. $4.47M in Q3 2021.","Cash, cash equivalents and marketable securities of $26.5M as of Sep 30, 2022.","R&D expenses were $2.98M for Q3 2022, down from $3.15M in Q3 2021.","FDA placed clinical hold on IkT-148009 for Parkinson's and MSA; 11 patients dosed with no serious adverse events.","Appointed Gisele Dion to Board of Directors as Audit Committee chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-287698","json":"https://secwatch.observer/filing/0001193125-22-287698.json","markdown":"https://secwatch.observer/filing/0001193125-22-287698.md","text":"https://secwatch.observer/filing/0001193125-22-287698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/0001193125-22-287698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/d409524d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T16:44:48.921959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"78fbe16ba7e3dda01587f6cf36f791166d59ca50","claim":"Inhibikase Therapeutics, Inc. reported three months ended September 30, 2022 results: net income $4.49 million, EPS $0.18 per share.","evidence_excerpt":"Net loss for the three months ended September 30, 2022 was $4.49 million, or $0.18 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/0001193125-22-287698-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Net income","value":"$4.49 million"},{"label":"EPS","value":"$0.18 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c8b2098ff4308410d51be9848c94a999c5585ad2","claim":"Inhibikase Therapeutics, Inc. reported nine months ended September 30, 2022 results: net income $13.78 million, EPS $0.55 per share.","evidence_excerpt":"Net loss for the nine months ended September 30, 2022, was $13.78 million or $0.55 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312522287698/0001193125-22-287698-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2022"},{"label":"Net income","value":"$13.78 million"},{"label":"EPS","value":"$0.55 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}